OptiBiotix Health Plc (AIM:OPTI)

Achilles Therapeutics Balance Sheet

Financials in millions GBP. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	0.74	0.64	1.05	2.01	0.86
Cash & Short-Term Investments	0.74	0.64	1.05	2.01	0.86
Cash Growth	16.38%	-39.64%	-47.58%	132.11%	89.79%
Accounts Receivable	0.31	0.35	0.38	1.42	0.51
Other Receivables	0.13	0.19	0.24	0.27	0.42
Receivables	0.45	0.54	0.62	1.69	0.93
Inventory	0.23	0.19	0.18	0.1	0.18
Prepaid Expenses	0.01	0.02	0.01	0.06	0.02
Total Current Assets	1.42	1.38	1.86	3.85	2.01
Long-Term Investments	6.51	6.69	8.15	13.65	8.96
Other Intangible Assets	1.12	1.33	1.54	2.64	2.74
Total Assets	9.05	9.4	11.55	20.15	13.7
Accounts Payable	0.27	0.06	0.19	0.42	0.36
Accrued Expenses	0.06	0.08	0.07	0.18	0.16
Other Current Liabilities	0.04	0.05	0.02	0	0
Total Current Liabilities	0.37	0.18	0.28	0.6	0.52
Long-Term Debt	-	-	-	0.82	0.77
Long-Term Deferred Tax Liabilities	0.28	0.35	0.37	0.55	0.56
Total Liabilities	0.65	0.53	0.64	1.97	1.85
Common Stock	1.96	1.82	1.82	1.76	1.76
Additional Paid-In Capital	4.11	2.96	2.96	2.54	2.54
Retained Earnings	0.59	1.82	3.68	11.32	5.06
Comprehensive Income & Other	1.75	2.27	2.44	2.52	2.46
Total Common Equity	8.4	8.87	10.91	18.14	11.82
Minority Interest	-	-	-	0.04	0.04
Shareholders' Equity	8.4	8.87	10.91	18.17	11.85
Total Liabilities & Equity	9.05	9.4	11.55	20.15	13.7
Total Debt	-	-	-	0.82	0.77
Net Cash (Debt)	0.74	0.64	1.05	1.19	0.09
Net Cash Growth	16.38%	-39.64%	-11.45%	1178.51%	-
Net Cash Per Share	0.01	0.01	0.01	0.01	0.00
Filing Date Shares Outstanding	97.94	91.19	91.19	87.94	87.94
Total Common Shares Outstanding	97.94	91.19	91.19	87.94	87.94
Working Capital	1.06	1.2	1.58	3.25	1.49
Book Value Per Share	0.09	0.10	0.12	0.21	0.13
Tangible Book Value	7.28	7.54	9.37	15.5	9.08
Tangible Book Value Per Share	0.07	0.08	0.10	0.18	0.10

Updated Sep 27, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.